NFKBIZ
NFKBIZ (NF-kappa-B inhibitor zeta) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Overview
Involved in regulation of NF-kappa-B transcription factor complexes. Inhibits NF-kappa-B activity without affecting its nuclear translocation upon stimulation. Inhibits DNA-binding of RELA and NFKB1/p50, and of the NF-kappa-B p65-p50 heterodimer and the NF-kappa-B p50-p50 homodimer.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NFKBIZ (NF-kappa-B inhibitor zeta) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
- 1 · What it is
NFKBIZ (NF-kappa-B inhibitor zeta) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
- 2 · What goes wrong in cancer
Involved in regulation of NF-kappa-B transcription factor complexes. Inhibits NF-kappa-B activity without affecting its nuclear translocation upon stimulation.
- 3 · How drugs use it
No product in this corpus aims at NFKBIZ yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:29805 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BYH8 (protein name, function text, keywords and locations (REST API)); CIViC gene NFKBIZ (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0))
Biology
Involved in regulation of NF-kappa-B transcription factor complexes. Inhibits NF-kappa-B activity without affecting its nuclear translocation upon stimulation. Inhibits DNA-binding of RELA and NFKB1/p50, and of the NF-kappa-B p65-p50 heterodimer and the NF-kappa-B p50-p50 homodimer. Also seems to activate NF-kappa-B-mediated transcription. In vitro, upon association with NFKB1/p50 has transcriptional activation activity and, together with NFKB1/p50 and RELA, is recruited to LCN2 promoters. Promotes transcription of LCN2 and DEFB4. Location: Nucleus (UniProt). Locus 3q12.3 (HGNC).
- Diffuse large B-cell lymphoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NFKBIZ" OR ABSTRACT:"NFKBIZ" OR TITLE:"NFKB inhibitor zeta" OR ABSTRACT:"NFKB inhibitor zeta" OR TITLE:"NF-kappa-B inhibitor zeta" OR ABSTRACT:"NF-kappa-B inhibitor zeta" OR TITLE:"FLJ34463" OR ABSTRACT:"FLJ34463") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NFKBIZ, not a curated reading list.